Report: New drugs needed for prostate cancer as incidents rise
Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand for new treatments, according to research from Datamonitor Healthcare.
The report estimates the number of prostate cancer incident cases in the five major EU markets of France, Germany, Italy, Spain and the UK will be 270,000 this year, and in the USA this number will be nearly 300,000. These numbers are forecast to increase by 27% and 20% respectively, reaching 340,000 and 360,000 by 2020.The UK alone is set for nearly 53,000 newly diagnosed cases in 2014, which will grow to 66,000 by 2020.
Prostate cancer is the second most common cancer in males. As the cancer progresses it can spread to other parts of the body and become metastatic castration-resistant prostate cancer (mCRPC), which is resistant to medical or surgical treatments that lower testosterone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze